The proposed brand name especially for the United States,  Prolacria is Diquafosol Tetrasodium ophthalmic solution – 2%, developed by the world renowned Inspire Pharmaceuticals of the United States. Inspire Pharmaceuticals is a biopharmaceutical company devoted to discover, develop and commercialize several prescription pharmaceutical formulations for the ailment sectors with considerable prospective and unexploited medical necessities. 

Prolacria is the ophthalmic solution 2% exclusively developed for treatment of dry eyes. The dry eyes have been described by inadequate tears and lubrication for appropriate protection of the cornea. The most usual symptoms of this ailment may be such as: pain, burning, foreign body sensation in the eye as well as sensitivity to lights. The drug typically functions as an agonist at the P2Y2 receptor, stimulating the discharge of three components of natural tears – mucin, lipids and fluids. The company is developing Prolacria in the form of an Eye Drops as Dry Eye treatment medication.

Inspire Pharmaceuticals, US has already concluded four phase three clinical trials for Prolacria Eye Drops for the ailment of dry eyes. Overall, the company is said to have carried out placebo controlled clinical trials of Prolacria in over 2,000 persons. Santen Pharmaceutical Co. Ltd – Japan is developing Diquafosol Tetrasodium ophthalmic solution in Japan. According to the Inspire Pharmaceutical’s agreement with Santen for developing Diquafosol Tetrasodium ophthalmic solution for the therapeutic treatments of ocular surface ailments such as Dry Eyes, in Japan as well as nine other Asian countries, besides providing some goals to be attained by Inspire Pharmaceuticals upon success of development targets by Santen.